APAC Oncology Trials: Growth Beyond the Headlines

Key Takeaways

• Oncology trial globalization analyses based on ClinicalTrials.gov document large absolute growth from 2000–2021, with China a leading early- and validation-phase location.
• WHO ICTRP aggregates East Asian registries (ChiCTR, JPRN, CRiS) that ClinicalTrials.gov alone can miss.
• APAC oncology share of regional starts is high relative to many other therapy areas, reflecting disease burden and treatment-naïve pools in some indications.
• Growth is not a free pass on data quality, inspection readiness, or bridging to U.S./EU labels.

What do registry analyses show about oncology globalization?

An ESMO Open quantitative analysis of 87,748 oncology clinical trials (2000–2021) recorded on ClinicalTrials.gov found substantial absolute annual growth and highlighted China’s role in early- and validation-phase activity. The authors also documented persistent geographic disparities in trial access.

Primary paper: doi.org/10.1016/j.esmoop.2024.104086 (ESMO Open, 2024).

Why ClinicalTrials.gov alone undercounts East Asia

Many East Asian studies register first in national systems. WHO’s ICTRP search portal consolidates primary registries worldwide, including China’s ChiCTR, Japan’s JPRN, and Korea’s CRiS. Competitive intelligence that ignores ICTRP will understate regional activity.

Portal: WHO ICTRP Search Portal. Sponsors should still use ClinicalTrials.gov for U.S.-facing and many industry global studies.

What is driving APAC oncology trial growth?

• Large patient populations and high cancer incidence in several APAC markets
• Expanding investigator networks and Phase 1 unit capacity, especially in China
• Regulatory modernization that can compress some start-up timelines relative to historical baselines

Industry analyses have previously reported decade-scale percentage increases in APAC oncology trial counts; treat third-party market tallies as directional and re-verify against registries for diligence.

What remains unproven for BD teams

Regional volume does not automatically equal registrational acceptance in the U.S. or EU. Endpoint selection, control-arm standards, assay centralization, and inspection history still decide whether APAC-heavy packages travel. Do not cite unverified “reduced scrutiny” as a strategy.

Practical diligence checklist

Confirm dual registration where required, map sites to known inspection outcomes, budget for translation and sample logistics, and pre-agree statistical analysis plans that regulators in destination markets will recognize.

Site selection realities in APAC oncology

High national trial counts can hide concentration in a handful of metro academic centers. Sponsors should model competitive enrollment, biopsy logistics, and radiology bandwidth site by site. Parallel start-up in Japan, South Korea, Australia, and China can diversify risk when a single country’s regulatory clock slips.

Ethics and data-integrity expectations are rising with volume. Budget for source-data verification intensity appropriate to first-in-region experience. Pair registry scans on ClinicalTrials.gov and ICTRP with investigator bibliography checks before committing Phase 3 slots.

Commercial teams should not equate APAC trial leadership with automatic first-launch sequencing. Pricing, HEOR evidence, and companion diagnostics still gate uptake after approval in each market.

Related NovaPharma coverage

• PMDA approves ENHERTU for HER2-low breast cancer
• India invites global pharma partnerships
• Clinical trials outsourcing market outlook

Primary Sources

1. ESMO Open — Globalization of clinical trials in oncology (DOI)
2. WHO — ICTRP Search Portal
3. ClinicalTrials.gov

Frequently Asked Questions